Welcome to our dedicated page for Invivyd SEC filings (Ticker: IVVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like Invivyd often means wading through hundreds of pages to locate one cash-runway table or a single trial update. If you have ever searched 鈥淚nvivyd SEC filings explained simply鈥� or wondered which variant data moved the share price, you know the challenge.
Stock Titan solves that problem. Our AI reads every Invivyd annual report 10-K simplified, parses each Invivyd quarterly earnings report 10-Q filing, and flags fresh Invivyd 8-K material events explained within minutes of hitting EDGAR. Interactive summaries highlight R&D spend, dilution risk, and regulatory milestones, while side-by-side charts let you compare pipeline disclosures over time.
Need real-time trade intel? Form 4 alerts surface Invivyd executive stock transactions Form 4, giving you immediate insight into insider sentiment. Our dashboard also groups every Invivyd proxy statement executive compensation section, so you can evaluate incentives driving decision-making.
- AI-powered summaries translate technical immunology terms into plain English
- Instant notifications for Invivyd Form 4 insider transactions real-time
- Side-by-side 鈥渞edline鈥� view of successive reports for quick change detection
Whether you type 鈥淚nvivyd earnings report filing analysis,鈥� 鈥渦nderstanding Invivyd SEC documents with AI,鈥� or 鈥淚nvivyd insider trading Form 4 transactions,鈥� this page delivers the answers鈥攁nd the filings鈥攚ithout the usual time sink.
Invivyd, Inc. reported operational and financing disclosures in its Form 10-Q, including capital structure, third-party agreements and program cost changes. The company noted Emergency Use Authorization for PEMGARDA in March 2024 and that sales of PEMGARDA have funded operations. During the period the company sold 9,000,000 shares under an at-the-market facility for net proceeds of $39.3 million at an average price of $4.50 per share and had $325 million of securities remaining on its shelf registration as of June 30, 2025. A $30 million Term Facility is available in three tranches subject to financial covenants and net product revenue milestones; as of June 30, 2025 the company had not met the revenue milestone required to draw on the earliest tranche. Material contractual items include significant Adimab obligations (quarterly fees of $0.6 million and royalty terms, including 45%鈥�55% on certain compulsory sublicenses), lease liabilities of $1.1 million (current) and $1.9 million (non-current), and stock plans and equity awards including 1,700,000 RSUs granted at $1.61 per share.
This Schedule 13G/A discloses that Maverick Capital, Ltd., Maverick Capital Management, LLC and Lee S. Ainslie III report beneficial ownership of 10,229,118 shares of Invivyd, Inc., representing 8.5% of the 119,961,445 outstanding shares reported as of May 1, 2025. The filing identifies the shares as held for Maverick clients across five funds: Maverick Fund USA, Ltd. (2,253,369), Maverick Fund II, Ltd. (2,210,410), Maverick Long Enhanced Fund, Ltd. (2,419,202), Maverick HP, L.P. (2,139,246) and Maverick Long Fund, Ltd. (1,206,891).
Each reporting person states shared voting and dispositive power over these shares and no sole voting or dispositive power. The document is filed as a Schedule 13G (Amendment No. 2) and includes a certification that the securities were not acquired to change or influence control of the issuer. The filing lists Maverick's Dallas, TX address and Mr. Ainslie's West Palm Beach, FL address and is signed on 08/14/2025.
Invivyd, Inc. (Nasdaq: IVVD) filed an 8-K to disclose that, on July 2, 2025, it issued a press release announcing the formation of the SPEAR (Spike Protein Elimination and Recovery) Study Group. The collaboration brings Invivyd together with leading researchers to evaluate the effects of the company鈥檚 monoclonal antibody therapy on two patient populations: 1) individuals suffering from Long COVID and 2) those experiencing COVID-19 post-vaccination syndrome.
The filing contains no financial results, trial data, or guidance. Instead, it simply furnishes the press release as Exhibit 99.1 under Item 8.01 (Other Events) and lists customary exhibit and signature information.
Invivyd (Nasdaq: IVVD) filed an 8-K under Item 8.01 to furnish a press release dated 26 June 2025.
The release reports positive full Phase 1/2 clinical data for VYD2311, a next-generation COVID-19 monoclonal antibody being pursued for both non-vaccine prophylaxis and treatment of active infection.
The document attaches the press release as Exhibit 99.1; no financial statements, guidance changes, or other material corporate actions were disclosed.
FAQ
What is the current stock price of Invivyd (IVVD)?
What is the market cap of Invivyd (IVVD)?
